Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · Real-Time Price · USD
8.30
+0.05 (0.61%)
At close: Dec 26, 2025, 4:00 PM EST
8.14
-0.16 (-1.93%)
After-hours: Dec 26, 2025, 4:41 PM EST
Lifecore Biomedical Revenue
Lifecore Biomedical had revenue of $19.29M in the quarter ending September 30, 2025, with 14.89% growth. This brings the company's revenue in the last twelve months to $74.83M, down -3.47% year-over-year. In the fiscal year ending May 25, 2025, Lifecore Biomedical had annual revenue of $72.33M, down -6.88%.
Revenue (ttm)
$74.83M
Revenue Growth
-3.47%
P/S Ratio
2.24
Revenue / Employee
$317,406
Employees
406
Market Cap
310.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 25, 2025 | 72.33M | -5.35M | -6.88% |
| May 26, 2024 | 77.67M | -21.57M | -21.74% |
| May 28, 2023 | 99.25M | -12.02M | -10.81% |
| May 29, 2022 | 111.27M | 10.40M | 10.31% |
| May 30, 2021 | 100.87M | -59.19M | -36.98% |
| May 31, 2020 | 160.07M | -397.49M | -71.29% |
| May 26, 2019 | 557.56M | 33.33M | 6.36% |
| May 27, 2018 | 524.23M | 54.45M | 11.59% |
| May 28, 2017 | 469.78M | -7.14M | -1.50% |
| May 29, 2016 | 476.92M | -62.34M | -11.56% |
| May 31, 2015 | 539.26M | 62.44M | 13.10% |
| May 25, 2014 | 476.81M | 35.11M | 7.95% |
| May 26, 2013 | 441.71M | 124.16M | 39.10% |
| May 27, 2012 | 317.55M | 44.21M | 16.18% |
| May 29, 2011 | 273.34M | 44.95M | 19.68% |
| May 30, 2010 | 228.39M | 3.99M | 1.78% |
| May 31, 2009 | 224.40M | -3.15M | -1.38% |
| May 25, 2008 | 227.55M | 25.66M | 12.71% |
| May 27, 2007 | 201.89M | -23.51M | -10.43% |
| May 28, 2006 | 225.40M | 24.38M | 12.13% |
| May 29, 2005 | 201.02M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LFCR News
- 3 days ago - HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 9 days ago - Lifecore Biomedical to be Added to Nasdaq Biotech Index - GlobeNewsWire
- 10 days ago - Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer - GlobeNewsWire
- 11 days ago - Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 19 days ago - Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 6 weeks ago - Lifecore Biomedical to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Lifecore Biomedical, Inc. (LFCR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update - GlobeNewsWire